← Back to Search

Amino Acid

L-glutamine for Diverticulosis

Phase 1
Waitlist Available
Research Sponsored by Emmaus Medical, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 48 weeks (12 months)
Awards & highlights

Summary

This trial is testing L-glutamine, a supplement that helps keep the gut healthy, on patients with diverticulosis. Diverticulosis causes small pouches in the colon that can be uncomfortable. The study aims to see if L-glutamine can reduce symptoms by supporting the gut lining and reducing inflammation. L-glutamine has been shown to reduce inflammation and support gut health in various gastrointestinal conditions.

Eligible Conditions
  • Diverticulosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 48 weeks (12 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 48 weeks (12 months) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change from baseline in the number of colonic diverticula via colonoscopy at 6 and 12 months in patients with diverticulosis.
Secondary study objectives
Change from baseline the size of colonic diverticula via colonoscopy at 6 and 12 months in patients with diverticulosis
Effect of oral L-glutamine on Hematological Parameters - Hematocrit
Effect of oral L-glutamine on Hematological Parameters - Hemoglobin
+4 more

Side effects data

From 2014 Phase 3 trial • 230 Patients • NCT01179217
81%
Sickle cell anaemia with crisis
25%
Constipation
23%
Nausea
22%
Pyrexia
21%
Headache
18%
Upper respiratory tract infection
17%
Cough
16%
Pain in extremity
15%
Vomiting
14%
Chest pain
13%
Back pain
13%
Arthralgia
12%
Abdominal pain
12%
Acute chest syndrome
11%
Abdominal pain upper
10%
Ocular icterus
9%
Pruritus
8%
Diarrhoea
8%
Acute Chest Syndrome
7%
Nasopharyngitis
7%
Urinary tract infection
7%
Nasal congestion
7%
Oropharnyngeal pain
6%
Fatigue
6%
Pneumonia
6%
Leukocytosis
5%
Anaemia
5%
Tachycardia
5%
Oedema peripheral
5%
Dizziness
5%
Dyspnoea
4%
Hypokalaemia
4%
Hypomanesaemia
3%
Asthma
3%
Bronchitis
3%
Gastroenteritis
3%
Hyperkalaemia
3%
Epistaxis
3%
Hypoxia
2%
Influenza
2%
Rash
1%
Leucocytosis
1%
Cardiac Arrest
1%
Gastritis
1%
Death
1%
Cholelithiasis
1%
Gastrointestinal viral infection
1%
Lobar pneumonia
1%
Osteomyelitis
1%
Pharnygitis streptococcal
1%
Sepsis
1%
Sinustitis
1%
Post-traumatic reaction
1%
Dehydration
1%
Joint effusion
1%
Transient ischaemic attack
1%
Haematuria
1%
Renal failure acute
1%
Bronchial hyperreactivity
1%
Pulmonary embolism
1%
Rhinitis allergic
1%
Skin ulcer
1%
Strabismus correction
1%
Aplastic anaemia
1%
Haemolysis
1%
Hypersplenism
1%
Pain
1%
Cholecystitis
1%
Cholecystitis acute
1%
Complication of device removal
1%
Device malfunction
1%
Fall
1%
Haemolytic transfusion reaction
1%
Pregnancy
1%
Deep vein thrombosis
1%
Thrombophlebits superficial
100%
80%
60%
40%
20%
0%
Study treatment Arm
L-glutamine
100% Maltodextrin

Trial Design

1Treatment groups
Experimental Treatment
Group I: L-glutamineExperimental Treatment1 Intervention
Participants received L-glutamine oral powder 15 grams twice daily for 48 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
L-Glutamine
FDA approved

Find a Location

Who is running the clinical trial?

Emmaus Medical, Inc.Lead Sponsor
7 Previous Clinical Trials
373 Total Patients Enrolled
Yutaka L Niihara, MDStudy ChairEmmaus Medical, Inc.
~1 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top